Andrew W. Hahn
YOU?
Author Swipe
View article: 1064 Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers
1064 Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers Open
View article: 1057 Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis
1057 Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis Open
View article: 20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518)
20Phase II trial of ivonescimab in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint blockade: IVORY trial (NCT06940518) Open
Background Immune checkpoint inhibitor (ICI)-based combinations, whether in the form of dual ICIs, or an ICI combined with a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI), constitute the first-line treatment for m…
View article: A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo)
A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo) Open
View article: Vigorous physical activity as a potential environmental risk factor in renal medullary carcinoma
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinoma Open
View article: Adaptation of the PREDIMED Intervention for Medically Underserved Prostate Cancer Patients Through Intervention Mapping
Adaptation of the PREDIMED Intervention for Medically Underserved Prostate Cancer Patients Through Intervention Mapping Open
Prostate cancer is the most common non-cutaneous malignancy for men and disproportionately affects those with low socioeconomic status, particularly men from racial and ethnic minority populations. This study describes the development of a…
View article: A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC Open
Background Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastati…
View article: GLP-1 Agonist Use Among Men with Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials
GLP-1 Agonist Use Among Men with Localized Prostate Cancer: A Narrative Review and Rationale for Prospective Clinical Trials Open
View article: MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer Open
View article: Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer
Leptin levels are associated with coronary artery calcification in patients with advanced prostate cancer Open
Background Convergent data suggest that advanced prostate cancer and coronary heart disease (CHD) share biological vulnerabilities that may be linked to adiposity. Here we explore whether leptin, as a marker and mediator of adiposity, coul…
View article: Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance
Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance Open
Background We previously reported that increases in circulating sphingolipids are associated with elevated risk of biopsy Gleason grade group (GG) upgrading in men on Active Surveillance (AS) for prostate cancer. Here, we aimed to validate…
View article: Design of Defensive Cybersecurity Architectures for High Temperature, Gas-Cooled Reactors
Design of Defensive Cybersecurity Architectures for High Temperature, Gas-Cooled Reactors Open
This report presents the design of defensive cybersecurity architectures (DCSAs) for High Temperature, Gas-Cooled Reactors (HTGRs). A DCSA is a cybersecurity design feature that places systems into security zones in a graded approach accor…
View article: OCTS-06 A PHASE II STUDY OF NIVOLUMAB WITH IPILIMUMAB AND CABOZANTINIB IN PATIENTS WITH UNTREATED RENAL CELL CARCINOMA BRAIN METASTASES
OCTS-06 A PHASE II STUDY OF NIVOLUMAB WITH IPILIMUMAB AND CABOZANTINIB IN PATIENTS WITH UNTREATED RENAL CELL CARCINOMA BRAIN METASTASES Open
BACKGROUND The incidence of brain metastases(mets) at the diagnosis of renal cell carcinoma (RCC) is 1.51%, and around 12% of patients(pts) with advanced RCC (aRCC) had brain mets. Brain mets confer a poor prognosis. Although systemic ther…
View article: Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy
Associations of SGLT-2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy Open
Background Studies have reported associations between prostate cancer, type II diabetes mellitus (T2DM) and cardiovascular disease in the context of treatment with hormone therapy (HT). This study aimed to assess the role of Sodium-Glucose…
View article: e3SIM: epidemiological-ecological-evolutionary simulation framework for genomic epidemiology
e3SIM: epidemiological-ecological-evolutionary simulation framework for genomic epidemiology Open
Infectious disease dynamics are driven by the complex interplay of epidemiological, ecological, and evolutionary processes. Accurately modeling these interactions is crucial for understanding pathogen spread and informing public health str…
View article: Supplementary Table S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Table S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Table S2. Pathogenic mutations in germline DNA.
View article: Supplementary Figure S11 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S11 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S11. Proportions of patients with AVPCmDNA and genomic alterations in p53, RB1, and PTEN in each group based on WES of metastatic tumor biopsies from patients in the Satisfactory group (n=37, in red) and in the Unsatis…
View article: Supplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S4. Immune cell densities by IHC across organ sites.
View article: Supplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S1. PSA and CTC status at module allocation, after 8 weeks of AAPA treatment.
View article: Supplementary Figure S9 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S9 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S9. Whole exome sequencing (WES)-based identification of pathogenic somatic mutations.
View article: Supplementary Figure S8 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S8 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) and Unsatis…
View article: Supplementary Figure S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S2. Failure-free survival in Modules 2 and 3.
View article: Supplementary Figure S3 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S3 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S3. Immune cell populations in baseline metastatic biopsies within Satisfactory and Unsatisfactory groups.
View article: Supplementary Figure S11 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S11 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S11. Proportions of patients with AVPCmDNA and genomic alterations in p53, RB1, and PTEN in each group based on WES of metastatic tumor biopsies from patients in the Satisfactory group (n=37, in red) and in the Unsatis…
View article: Supplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S4 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S4. Immune cell densities by IHC across organ sites.
View article: Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S7 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S7. Major immune cell types derived from bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (S) and Unsatisfactory (US) groups.
View article: Supplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S1 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S1. PSA and CTC status at module allocation, after 8 weeks of AAPA treatment.
View article: Supplementary Figure S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S2 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S2. Failure-free survival in Modules 2 and 3.
View article: Supplementary Figure S6 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S6 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S6. Pathway enrichment analysis.
View article: Supplementary Figure S8 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Supplementary Figure S8 from A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer Open
Supplementary Figure S8. Heatmap showing immune-related Level 1 Reactome and selected Cancer Hallmark pathways in bulk RNA sequencing of baseline metastatic lymph node biopsies from patients allocated to the Satisfactory (n=27) and Unsatis…